<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33786805</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1113</StartPage><EndPage>1126</EndPage><MedlinePgn>1113-1126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-021-01025-6</ELocationID><Abstract><AbstractText>Glial cell line-derived neurotrophic factor (GDNF) is a powerful neuroprotective growth factor. However, systemic or intrathecal administration of GDNF is associated with side effects. Here, we aimed to avoid this by restricting the transgene expression to the skeletal muscle by gene therapy. To specifically target most skeletal muscles in the mouse model of amyotrophic lateral sclerosis (ALS), SOD1<sup>G93A</sup> transgenic mice were intravenously injected with adeno-associated vectors coding for GDNF under the control of the desmin promoter. Treated and control SOD1<sup>G93A</sup> mice were evaluated by rotarod and nerve conduction tests from 8 to 20&#xa0;weeks of age, and then histological and molecular analyses were performed. Muscle-specific GDNF expression delayed the progression of the disease in SOD1<sup>G93A</sup> female and male mice by preserving the neuromuscular function; increasing the number of innervated neuromuscular junctions, the survival of spinal motoneurons; and reducing glial reactivity in treated SOD1<sup>G93A</sup> mice. These beneficial actions are attributed to a paracrine protective mechanism from the muscle to the motoneurons by GDNF. Importantly, no adverse secondary effects were detected. These results highlight the potential of muscle GDNF-targeted expression for ALS therapy.</AbstractText><CopyrightInformation>&#xa9; 2021. The American Society for Experimental NeuroTherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>M&#xf2;dol-Caballero</LastName><ForeName>Guillem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Lareu</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verd&#xe9;s</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat Mixta UAB-VHIR, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Vales</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pag&#xe8;s</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chill&#xf3;n</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat Mixta UAB-VHIR, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Catal&#xe0; de Recerca I Estudis Avan&#xe7;ats (ICREA), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain. xavier.navarro@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. xavier.navarro@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. xavier.navarro@uab.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Assumpci&#xf3;</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7205-2796</Identifier><AffiliationInfo><Affiliation>Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain. assumpcio.bosch@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. assumpcio.bosch@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. assumpcio.bosch@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat Mixta UAB-VHIR, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain. assumpcio.bosch@uab.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495040">Gdnf protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">GDNF</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Motoneuron</Keyword><Keyword MajorTopicYN="N">Neuromuscular junction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33786805</ArticleId><ArticleId IdType="pmc">PMC8423878</ArticleId><ArticleId IdType="doi">10.1007/s13311-021-01025-6</ArticleId><ArticleId IdType="pii">10.1007/s13311-021-01025-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog Neurobiol. 2015;133:1&#x2013;26. doi: 10.1016/j.pneurobio.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.07.004</ArticleId><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233&#x2013;241. doi: 10.1212/WNL.47.6_Suppl_4.233S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.233S</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Jesse S. Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther Adv Neurol Disord. 2009;2:319&#x2013;326. doi: 10.1177/1756285609336399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285609336399</ArticleId><ArticleId IdType="pmc">PMC3002601</ArticleId><ArticleId IdType="pubmed">21180622</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128:3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med 2018;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a Mouse Model of ALS by In Vivo Base Editing. Mol Ther. 2020;28:1177&#x2013;1189. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Santos-Nogueira E, Osta R, et al. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol. 2011;122:1660&#x2013;1670. doi: 10.1016/j.clinph.2011.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.01.045</ArticleId><ArticleId IdType="pubmed">21354365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Martinez-Muriana A, Leiva T, et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation. Neurobiol Dis. 2016;95:168&#x2013;178. doi: 10.1016/j.nbd.2016.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.023</ArticleId><ArticleId IdType="pubmed">27461051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechade C, Mallecourt C, Sedel F, et al. Motoneuron-derived neurotrophin-3 is a survival factor for PAX2-expressing spinal interneurons. J Neurosci. 2002;22:8779&#x2013;8784. doi: 10.1523/JNEUROSCI.22-20-08779.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-20-08779.2002</ArticleId><ArticleId IdType="pmc">PMC6757685</ArticleId><ArticleId IdType="pubmed">12388583</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugas JC, Mandemakers W, Rogers M, et al. A novel purification method for CNS projection neurons leads to the identification of brain vascular cells as a source of trophic support for corticospinal motor neurons. J Neurosci. 2008;28:8294&#x2013;8305. doi: 10.1523/JNEUROSCI.2010-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2010-08.2008</ArticleId><ArticleId IdType="pmc">PMC2567869</ArticleId><ArticleId IdType="pubmed">18701692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda O, Murakami M, Ino H, et al. Acute up-regulation of brain-derived neurotrophic factor expression resulting from experimentally induced injury in the rat spinal cord. Acta Neuropathol. 2001;102:239&#x2013;245. doi: 10.1007/s004010000357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010000357</ArticleId><ArticleId IdType="pubmed">11585248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovar YRLB, Ramirez-Jarquin UN, Lazo-Gomez R, et al. Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy. Front Cell Neurosci. 2014;8:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937589</ArticleId><ArticleId IdType="pubmed">24616665</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413&#x2013;417. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The, "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther. 2008;16:1056&#x2013;1064. doi: 10.1038/mt.2008.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.60</ArticleId><ArticleId IdType="pmc">PMC2737251</ArticleId><ArticleId IdType="pubmed">18388910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839&#x2013;842. doi: 10.1126/science.1086137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002;22:6920&#x2013;6928. doi: 10.1523/JNEUROSCI.22-16-06920.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-16-06920.2002</ArticleId><ArticleId IdType="pmc">PMC6757879</ArticleId><ArticleId IdType="pubmed">12177190</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson CE, Phillips HS, Pollock RA, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266:1062&#x2013;1064. doi: 10.1126/science.7973664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7973664</ArticleId><ArticleId IdType="pubmed">7973664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez CF, Andressoo JO. Biology of GDNF and its receptors - Relevance for disorders of the central nervous system. Neurobiol Dis. 2017;97:80&#x2013;89. doi: 10.1016/j.nbd.2016.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.021</ArticleId><ArticleId IdType="pubmed">26829643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130&#x2013;1132. doi: 10.1126/science.8493557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8493557</ArticleId><ArticleId IdType="pubmed">8493557</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers R, Hendriks WT, Tannemaat MR, et al. Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots. Mol Cell Neurosci. 2008;39:105&#x2013;117. doi: 10.1016/j.mcn.2008.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2008.05.018</ArticleId><ArticleId IdType="pubmed">18585464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gash DM, Zhang Z, Ai Y, et al. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol. 2005;58:224&#x2013;233. doi: 10.1002/ana.20549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20549</ArticleId><ArticleId IdType="pubmed">16049934</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakowicz WP, Staples CS, Milbrandt J, et al. Glial cell line-derived neurotrophic factor promotes the survival of early postnatal spinal motor neurons in the lateral and medial motor columns in slice culture. J Neurosci. 2002;22:3953&#x2013;3962. doi: 10.1523/JNEUROSCI.22-10-03953.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-10-03953.2002</ArticleId><ArticleId IdType="pmc">PMC6757646</ArticleId><ArticleId IdType="pubmed">12019314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther. 1997;282:1396&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">9316852</ArticleId></ArticleIdList></Reference><Reference><Citation>Acsadi G, Anguelov RA, Yang H, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther. 2002;13:1047&#x2013;1059. doi: 10.1089/104303402753812458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104303402753812458</ArticleId><ArticleId IdType="pubmed">12067438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YY, Wang LJ, Muramatsu S, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci Res. 2003;45:33&#x2013;40. doi: 10.1016/S0168-0102(02)00195-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-0102(02)00195-5</ArticleId><ArticleId IdType="pubmed">12507722</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe Y, Nagano I, Gazi MS, et al. Glial cell line-derived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Neurol Res. 2003;25:195&#x2013;200. doi: 10.1179/016164103101201193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164103101201193</ArticleId><ArticleId IdType="pubmed">12635522</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, McHugh J, Tork C, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007;2:e689. doi: 10.1371/journal.pone.0000689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000689</ArticleId><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Alkaslasi M, Vit JP, et al. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1(G93A) ALS rat but has adverse side effects. Gene Ther. 2017;24:245&#x2013;252. doi: 10.1038/gt.2017.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.9</ArticleId><ArticleId IdType="pmc">PMC5404206</ArticleId><ArticleId IdType="pubmed">28276446</ArticleId></ArticleIdList></Reference><Reference><Citation>Luz M, Mohr E, Fibiger HC. GDNF-induced cerebellar toxicity: A brief review. Neurotoxicology. 2016;52:46&#x2013;56. doi: 10.1016/j.neuro.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2015.10.011</ArticleId><ArticleId IdType="pubmed">26535469</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973&#x2013;985. doi: 10.1038/sj.gt.3300938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3300938</ArticleId><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Cudkowicz M, Brown RH., Jr Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:603&#x2013;607. doi: 10.1002/mus.20628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20628</ArticleId><ArticleId IdType="pubmed">16892429</ArticleId></ArticleIdList></Reference><Reference><Citation>Homs J, Ariza L, Pages G, et al. Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther. 2011;18:622&#x2013;630. doi: 10.1038/gt.2011.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2011.7</ArticleId><ArticleId IdType="pubmed">21326330</ArticleId></ArticleIdList></Reference><Reference><Citation>Modol-Caballero G, Herrando-Grabulosa M, Garcia-Lareu B, et al. Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1(G93A) ALS mice. Neurobiol Dis. 2020;137:104793. doi: 10.1016/j.nbd.2020.104793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104793</ArticleId><ArticleId IdType="pubmed">32032731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakai H, Herzog RW, Hagstrom JN, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 1998;91:4600&#x2013;4607. doi: 10.1182/blood.V91.12.4600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V91.12.4600</ArticleId><ArticleId IdType="pubmed">9616156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Olivan S, Mancera P, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:302&#x2013;310. doi: 10.3109/17482968.2012.662688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662688</ArticleId><ArticleId IdType="pubmed">22424126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberg MB, Brownell AA. Motor unit number estimation in the assessment of performance and function in motor neuron disease. Phys Med Rehabil Clin N Am. 2008;19(509&#x2013;532):ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">18625413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68:1402&#x2013;1410. doi: 10.1212/01.wnl.0000260065.57832.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260065.57832.87</ArticleId><ArticleId IdType="pubmed">17452585</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 1996;85:1113&#x2013;1124. doi: 10.1016/S0092-8674(00)81311-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81311-2</ArticleId><ArticleId IdType="pubmed">8674117</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature. 1996;382:80&#x2013;83. doi: 10.1038/382080a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382080a0</ArticleId><ArticleId IdType="pubmed">8657309</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci. 2003;116:3855&#x2013;3862. doi: 10.1242/jcs.00786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00786</ArticleId><ArticleId IdType="pubmed">12953054</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JA, Fischbach GD. Neurotrophic factors increase neuregulin expression in embryonic ventral spinal cord neurons. J Neurosci. 1997;17:1416&#x2013;1424. doi: 10.1523/JNEUROSCI.17-04-01416.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-04-01416.1997</ArticleId><ArticleId IdType="pmc">PMC6793741</ArticleId><ArticleId IdType="pubmed">9006983</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JA, Hmadcha A, Fischbach GD, et al. Neuregulin expression at neuromuscular synapses is modulated by synaptic activity and neurotrophic factors. J Neurosci. 2002;22:2206&#x2013;2214. doi: 10.1523/JNEUROSCI.22-06-02206.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-06-02206.2002</ArticleId><ArticleId IdType="pmc">PMC6758272</ArticleId><ArticleId IdType="pubmed">11896160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li Y, Paudyal R, et al. Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI. J Neurol Sci. 2015;357:28&#x2013;34. doi: 10.1016/j.jns.2015.06.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.055</ArticleId><ArticleId IdType="pmc">PMC6691739</ArticleId><ArticleId IdType="pubmed">26183085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn MC, Connor B, Kozlowski DA, et al. Gene transfer for neuroprotection in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Novartis Found Symp 2000;231:70&#x2013;89;discussion 89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11131547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Mitsuma N, Inukai A, et al. Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases. Neurochem Res. 1999;24:785&#x2013;790. doi: 10.1023/A:1020739831778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1020739831778</ArticleId><ArticleId IdType="pubmed">10447463</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Brakefield D, Pan Y, et al. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol. 2007;203:457&#x2013;471. doi: 10.1016/j.expneurol.2006.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.08.028</ArticleId><ArticleId IdType="pubmed">17034790</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot S, Azzouz M, Deglon N, et al. Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis. 2004;16:139&#x2013;149. doi: 10.1016/j.nbd.2004.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.01.017</ArticleId><ArticleId IdType="pubmed">15207271</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther. 2008;16:2002&#x2013;2010. doi: 10.1038/mt.2008.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.197</ArticleId><ArticleId IdType="pmc">PMC2678899</ArticleId><ArticleId IdType="pubmed">18797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Igoa M, Calvo AC, Ciriza J, et al. Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model. Restor Neurol Neurosci. 2012;30:69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22124037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kobayashi Y, Li M, et al. In vivo gene electroporation of glial cell line-derived neurotrophic factor (GDNF) into skeletal muscle of SOD1 mutant mice. Neurochem Res. 2001;26:1201&#x2013;1207. doi: 10.1023/A:1013959121424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1013959121424</ArticleId><ArticleId IdType="pubmed">11874201</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Chiang P, Wang J, et al. Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2012;71:104&#x2013;115. doi: 10.1097/NEN.0b013e3182423c43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182423c43</ArticleId><ArticleId IdType="pmc">PMC3270561</ArticleId><ArticleId IdType="pubmed">22249457</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JA. Neuregulin: an activity-dependent synaptic modulator at the neuromuscular junction. J Neurocytol. 2003;32:649&#x2013;664. doi: 10.1023/B:NEUR.0000020640.84708.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:NEUR.0000020640.84708.35</ArticleId><ArticleId IdType="pubmed">15034258</ArticleId></ArticleIdList></Reference><Reference><Citation>Modol-Caballero G, Garcia-Lareu B, Verdes S et al. Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis. Neurotherapeutics 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609630</ArticleId><ArticleId IdType="pubmed">31965551</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie F, Zhang F, Min S, et al. Glial cell line-derived neurotrophic factor (GDNF) attenuates the peripheral neuromuscular dysfunction without inhibiting the activation of spinal microglia/monocyte. BMC Geriatr. 2018;18:110. doi: 10.1186/s12877-018-0796-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-018-0796-1</ArticleId><ArticleId IdType="pmc">PMC5944173</ArticleId><ArticleId IdType="pubmed">29743034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahavi EE, Ionescu A, Gluska S, et al. A compartmentalized microfluidic neuromuscular co-culture system reveals spatial aspects of GDNF functions. J Cell Sci. 2015;128:1241&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359927</ArticleId><ArticleId IdType="pubmed">25632161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>